Medical Therapy. Efficacy or Lack of Efficacy

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study

Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken‐Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice […]

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study Read More »

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience

Azadeh Issapour, Benjamin Frank, Sarah Crook, Michelle D. Hite, Michelle L. Dorn, Erika B. Rosenzweig, D. Dunbar Ivy, Usha S. KrishnanColumbia University Irving Medical Center. University of Colorado and Children’s Hospital Colorado.United States Pediatric PulmonologyPediatr Pulmonol 2022; 57: 724-733DOI: 10.1002/ppul.25796 AbstractObjective: To describe the safety and tolerability of treatment with ambrisentan and tadalafil in pediatric pulmonary hypertension

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience Read More »

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine

Johannes M. Douwes, Willemijn M. H. Zijlstra, Erika B. Rosenzweig, Mark-Jan Ploegstra, Usha S. Krishnan, Meindina G. Haarman, Marcus T. R. Roofthooft, Douwe Postmus, Hans L. Hillege, D. Dunbar Ivy, Rolf M. F. BergerUniversity of Groningen, University Medical Center Groningen and Beatrix Children’s Hospital. Columbia University. University of Colorado, Children’s Hospital Colorado.Netherlands and United States

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine Read More »

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient

David Procaccini, Dennis Delany, Abigail Self, Patricia Lawrence Kane, John D. CoulsonJohns Hopkins HospitalUnited States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2023; 28: 102-107DOI: 10.5863/1551-6776-28.1.102 AbstractWe report a case of a 7-year old male with idiopathic pulmonary arterial hypertension, successfully transitioned from an intravenous infusion to inhaled treprostinil during inpatient admission, after his

Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient Read More »

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation

Thomas R. Fleming, Christine E. Garnett, Laurie S. Conklin, Solange Corriol‑Rohou, Sudharshan Hariharan, Daphne Hsu, Guenther Mueller‑Velten, Yeruk Mulugeta, Ronald Portman, Mark D. Rothmann, Norman L. Stockbridge, Simon Wandel, Jialu Zhang, Lynne YaoUniversity of Washington. U.S. Food and Drug Administration. Janssen Research and Development. AstraZeneca. Children’s Hospital at Montefiore and Albert Einstein College of Medicine. Novartis Pharma AG and Novartis Pharmaceuticals.United States Therapeutic Innovation and Regulatory ScienceTher Innov Regul Sci 2023; 57: 109-120DOI: 10.1007/s43441-022-00445-6 AbstractEven with recent substantive improvements in health care in pediatric populations, considerable need remains

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation Read More »

Ambrisentan for in pediatric pulmonary arterial hypertension: a cost-utility analysis

Jefferson Antonio Buendia, Diana Guerrero Patino, Erika Fernanda LindarteUniversity of Antioquia.Columbia Pediatric PulmonologyPediatr Pulmonol 2023; DOI: 10.1002/ppul.26361 AbstractIntroduction: Despite the growing evidence of efficacy, little is known regarding the efficiency of ambrisentan to decrease cost and improve the functional classes of pediatric patients with Pulmonary arterial hypertension. This study aims to determine the cost-utility of ambrisentan regarding

Ambrisentan for in pediatric pulmonary arterial hypertension: a cost-utility analysis Read More »

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates University of Alberta and Stollery Children’s Hospital. Medical College of Wisconsin.Canada and United States Frontiers in PediatricsFront Pediatr 2023; DOI: 10.3389/fped.2023.1055131 AbstractIntroduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience Read More »

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Marc Humbert, Vallerie McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Hossein-Ardeschir Ghofrani, Pilar Escribano Subias, Jeremy Feldman, Gisela Meyer, David Montani, Karen M. Olsson, Solaiappan Manimaran, Jennifer Barnes, Peter G. Linde, Janethe de Oliveira Pena, David B. BadeschPULSAR Trial Investigators.France, United States, United Kingdom,

Sotatercept for the Treatment of Pulmonary Arterial Hypertension Read More »

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Marc Humbert, Vallerie McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Hossein-Ardeschir Ghofrani, Pilar Escribano Subias1, Jeremy Feldman, Gisela Meyer, David Montani, Karen M. Olsson, Solaiappan Manimaran, Janethe de Oliveira Pena, David B. BadeschHôpital Bicêtre, Assistance Publique-Hôpitaux de Paris. University of Michigan Health System. Imperial

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension Read More »

Management of Complex Pulmonary Vein Stenosis at Altitude Combining Comprehensive Percutaneous Interventional Treatment with Sirolimus, Pulmonary Hypertension Medications and Intraluminal Imaging with Optical Coherence Tomography

Michael J. Shorofsky, Gareth J. Morgan, Ernesto Mejia, Salvador A. Rodriguez, Megan Greene, Paige Sheaks, Dunbar Ivy, Jenny E. ZablahUniversity of Colorado and Children’s Hospital Colorado.United States Pediatric CardiologyPediatr Cardiol 2023; DOI: 10.1007/s00246-023-03102-3 AbstractBackground: Pulmonary vein stenosis (PVS) is a growing problem for the pediatric congenital heart population. Sirolimus has previously been shown to improve survival and

Management of Complex Pulmonary Vein Stenosis at Altitude Combining Comprehensive Percutaneous Interventional Treatment with Sirolimus, Pulmonary Hypertension Medications and Intraluminal Imaging with Optical Coherence Tomography Read More »

Scroll to Top